Ranbaxy Reportedly Hit With Another $40 Million U.S. Fine
This article was originally published in PharmAsia News
Executive Summary
The U.S. Justice Department has slapped Ranbaxy Laboratories with another $40 million fine for production violations, this one at its already banned API plant in Toansa, sources say.